Graphene is an allotrope of carbon and the basic structural element of other allotropes such as graphite and carbon nanotubes. It’s one of the lightest materials known and the strongest compound discovered. With its exceptional mechanical stiffness, strength, elasticity, high surface area and outstanding electrical and thermal conductivity, Graphene is ideal for use in electronics, sensors, biomedical technologies, protective coatings, energy and composite applications.
Accelerate development of adoptive cell therapies
Sponsored PublicationsThe success of any adoptive cell therapy lies in how effectively and selectively engineered immune cells interact and kill cancer cells. Functional phenomics enables insights that can dramatically accelerate the development of next-gen cell therapies. evorion biotechnologies brings functional phenomics to pharma and biotech partners via exclusive access to a unique, proprietary pipeline for in-depth multi-modal analysis of thousands of cell-cell interactions at single-cell resolution.
BioNTech investigates cancer vaccine BNT122 in Phase II trial
Latest NewsBionTech SE, which has been very successful in the field of corona vaccines, is starting phase II tests with its colorectal cancer candidate BNT122.
Bulletproof your supply chain
Sponsored PublicationsThis whitepaper provides insights into why it is critical to manage, optimize and streamline a supply chain to mitigate risks, such as those brought on by the COVID-19 pandemic.
Aseptic Closed Small-Volume Processing: Today’s Option`s
Sponsored PublicationsSmall-volume biopharmaceutical processes continue to grow as more biopharmaceutical, cell therapy and gene therapy companies develop products. A 2021 Association for Regenerative Medicine (ARM) report states that there are 1,085 cell, gene and tissue-based therapy developers worldwide. These companies are engaged in many small-volume (<10L) processes including early-stage drug development and autologous therapies.
Advent France Biotechnology launches €86m fund
Latest NewsAdvent France Biotechnology’s has launched a second biotech seed fund with a first close at €86m. Since 2017, the French state fund has financed 15 startups in France, Spain, Belgium and Ireland with €68m.
Let Excelya recruit the right people for the early phase
Sponsored PublicationsEarly phase clinical trials require expert support, often across many service areas and specialisms. Recruitment for trials can be complicated, with less flexibility and higher costs as you attempt to acquire top talent on a project-only basis. That’s why CROs are becoming increasingly indispensable. CROs offer fully formed, multi-skilled teams ready to go, who you can bring on board as and when needed.
UK clears the way for gene-edited crops
Latest NewsPost-Brexit, UK ditches the strict EU regulation for genetic engineering: in future, gene-edited crops will be assessed just like any other new variety, the government said.
mRNA – delivering on the promises
OpinionThe past two years could be called the years of messenger RNA (mRNA) technology, with two major biotech companies, BioNTech and Moderna, playing a crucial role in the development of vaccines against COVID-19 and showing the world the way out of the pandemic, along with achieving record sales revenues.
Team identifies factors for COVID-19 vaccine protection
Latest NewsA comparison of immune correlates of AstraZeneca’s Phase II/III COVID-19 vaccine trial shows what antibodiy titer is required to prevent symptomatic disease.
Graphene
ProductsGraphene is an allotrope of carbon and the basic structural element of other allotropes such as graphite and carbon nanotubes. It’s one of the lightest materials known and the strongest compound discovered. With its exceptional mechanical stiffness, strength, elasticity, high surface area and outstanding electrical and thermal conductivity, Graphene is ideal for use in electronics, sensors, biomedical technologies, protective coatings, energy and composite applications.